New drug combo aims to slow advanced lung cancer in first-line treatment

NCT ID NCT06670196

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 15 times

Summary

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 420 adults who have not had prior treatment for advanced disease will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination delays cancer growth or improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-Sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER